STAT3 inhibitors for cancer therapy: Have all roads been explored?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor in cell growth, constitutively activated in approximately 70% of human cancers.
• Activated STAT3 promotes tumor cell survival and proliferation, making it a significant therapeutic target.
• Existing STAT3 inhibitors lack specificity, often affecting STAT1, which is involved in apoptosis and immune responses.

Purpose of the Study:

• To explore novel strategies for inhibiting STAT3 activity in cancer cells.
• To develop STAT3 inhibitors with high specificity, avoiding interference with STAT1 function.
• To investigate the potential of targeting the STAT3 DNA-binding domain (DBD) for selective inhibition.

Main Methods:

• Investigated STAT3 dimerization via phosphotyrosine/src homology 2 (SH2) domain interaction.
• Explored inhibition using SH2 ligands, including G quartet oligodeoxynucleotides (ODN) and small molecules.
• Designed and evaluated decoy oligodeoxynucleotides (dODN) targeting STAT3, with a focus on specificity against STAT1.

Main Results:

• STAT3 inhibition leads to tumor cell death, confirming its role as a viable anticancer target.
• A specific STAT3 decoy ODN was designed to target the STAT3 DNA-binding domain (DBD).
• This specific dODN demonstrated no interference with STAT1-mediated cell death pathways.

Conclusions:

• Targeting STAT3 is a promising strategy for cancer therapy.
• Development of STAT3-specific inhibitors, particularly those targeting the DBD, is crucial for effective and safe treatment.
• Further research into DBD-targeting inhibitors with STAT3/STAT1 discriminating ability is warranted.